CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: A Phase II Study of the Anti-CCR4 Antibody Mogamulizumab in Patients with Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma.